Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors

Rhea-AI Summary

Kestra Medical Technologies (NASDAQ: KMTS) has appointed Conor Hanley as an independent director to its board, effective June 4, 2025. Hanley brings significant expertise in medical technology and cardiac care as the current CEO of FIRE1, a connected medical device company focused on heart failure solutions. His extensive experience includes senior management roles at ResMed, where he led the cardiology business unit and chronic disease management solutions globally. Hanley was also co-founder and CEO of BiancaMed, later acquired by ResMed. He holds a PhD in chemical engineering from the University of Pennsylvania and an MBA from INSEAD. The appointment aims to support Kestra's growth and expansion of its ASSURE® system in the wearable cardioverter defibrillator market.

Positive

• Appointment of experienced medical technology executive with specific expertise in cardiology and heart failure solutions
• Strategic addition to support company's growth and ASSURE® system expansion
• New director brings valuable experience from successful medical device companies (FIRE1, ResMed, BiancaMed)

Negative

• None.

KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025.

“I am delighted to welcome Conor to our board of directors,” said Brian Webster, President and CEO of Kestra Medical Technologies. “He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE^® system.”

Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device solutions company dedicated to improving outcomes for people with heart failure. He previously held senior management roles at ResMed, including leading the cardiology business unit and chronic disease management solutions globally. Prior to ResMed, Mr. Hanley was co-founder and CEO of BiancaMed, a medical device company that was acquired by ResMed. Mr. Hanley earned a PhD in chemical engineering from the University of Pennsylvania and an MBA from INSEAD. His previous board experience includes Enterprise Ireland and chair of APC Ltd. and the Irish MedTech association.

“I am honored to join the Kestra board of directors,” said Mr. Hanley. “Kestra is driving much-needed innovation in the wearable cardioverter defibrillator market, and I look forward to collaborating with the management team as the company scales its operations and delivers on its commitments to patients and prescribers.”

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

FAQ

Who is the new board director at Kestra Medical Technologies (KMTS)?

Conor Hanley, CEO of FIRE1 and former ResMed executive, was appointed as an independent director effective June 4, 2025.

What is Conor Hanley's background and experience before joining KMTS board?

Hanley is CEO of FIRE1, held senior management roles at ResMed leading cardiology and chronic disease management, and was co-founder/CEO of BiancaMed. He has a PhD in chemical engineering and MBA from INSEAD.

What is Kestra Medical Technologies' (KMTS) main product?

Kestra Medical Technologies develops the ASSURE® system, a wearable cardioverter defibrillator.

How will Conor Hanley's appointment benefit KMTS?

Hanley's expertise in medical technology and cardiac care will serve as a strategic resource for growing and expanding the reach of Kestra's ASSURE® system.

When did Conor Hanley join Kestra Medical Technologies' board?

Conor Hanley joined Kestra Medical Technologies' board as an independent director effective June 4, 2025.